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Abstract
A normally functioning menstrual cycle requires significant crosstalk between hormones originating in ovar-
ian and brain tissues. Reproductive hormone dysregulation may cause abnormal function and sometimes
infertility. The inherent complexity in this endocrine system is a challenge to identifying mechanisms of
cycle disruption, particularly given the large number of unknown parameters in existing mathematical
models. We develop a new endocrine model to limit model complexity and use simulated distributions of
unknown parameters for model analysis. By employing a comprehensive model evaluation, we identify a
collection of mechanisms that differentiate normal and abnormal phenotypes. We also discover an intermedi-
ate phenotype–displaying relatively normal hormone levels and cycle dynamics–that is grouped statistically
with the irregular phenotype. Results provide insight into how clinical symptoms associated with ovulatory
disruption may not be detected through hormone measurements alone.
1. Introduction
Female endocrine physiology is relatively poorly understood and is related to several high-impact diseases—
including polycystic ovary syndrome (PCOS), endometriosis, and diabetes-related illnesses like non-alcoholic
fatty liver disease—along with general reproductive health and mental health. Here we are primarily mo-
tivated by two of these: PCOS, a condition where menstrual periods are infrequent or prolonged and/or
where excess male hormone (androgen) levels are present, and endometriosis, a condition where uterine-
lining tissue grows throughout the body. Both conditions lead to severe complications and reduced quality
of life. The systems physiologic understanding of such conditions are poorly understood, and few data and
few models exist to explain their origin or to provide a basis for high-fidelity phenotypes.
We want to forge the path for better understanding of female endocrine physiology anchored with math-
ematical physiology. The pathway for using quantitative descriptions of physiology to impact human health
is non-trivial: (1) physiologic systems are complex; (2) mathematical models of physiology do not rely on
first principles, but are rather idealizations of how we imagine the physiologic subsystems to function; (3)
model verification is also complex, requiring data and a means of evaluating the model’s ability to represent
those data; (4) models and parameters must be personalized and synchronized with patient data; and, (5)
translation of the model-based information is difficult and complicated.
Within clinical practice, the most common usage of physiology is for reasoning by analogy or via qual-
itative relationships. For example, in an ICU we inject insulin to reduce dangerously high glucose levels,
and this is done incrementally with a dose chosen to be small enough to avoid hypoglycemia. We want to
move beyond this reason-by-analogy approach; but, in addition to the complexity of clinical data, there are
roadblocks, such as a lack of data for validation, no direct translation between complex quantitative physio-
logic information and the clinical setting, and the subsequent lack of clinical entry points. Nevertheless, the
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problems we choose to tackle, along with the basic construction and usage of related models, can be directed
by the real potential to impact our understanding of health, especially as far as informed decision-making
and plausible data collection are concerned.
Here we focus on the subsystem of the female endocrine system that is thought to control the ovula-
tory cycle. In the qualitative, physiologically mechanistic, mathematical context, descriptions of ovulatory
dysfunction are complicated. First, the physiology is complex: there are multiple mechanisms, both in the
brain and in the ovaries, that can alter ovulatory function. Second, and more problematic, we are extremely
data-limited: even qualitatively, there is no systematic, comprehensive way to classify dysfunction because
dynamical time scales are long (months to years), intra- and inter-personal variability is high, and observable
manifestation of dysfunction can have many sources whose delineation can be difficult to resolve with data.
The invasiveness of collection procedures adds to the limited data at our disposal.
The data that can exist include primary reproductive hormone measurements, which are useful for
delineating broadly defined clinical abnormalities and quantifying generalized ovulatory states. For example,
two prototypical data sets reported in the literature include pituitary and ovarian hormones collected daily
over the course of a typical cycle [1, 2]; we use the data in [1] in this paper. The challenge is these
data may only provide a partial view to more subtle abnormalities. For example, PCOS can result in the
complete absence of, or sporadic, ovulation. But, distinguishing between mechanisms governing these two
observable clinical manifestations is difficult because clinically feasible diagnostic tools rely on measurements
taken either at a single time point or over the course of a few hours [3]. We would require data spanning
multiple months in order to build a comprehensive hormone profile with any hope of revealing important
reproductive features, especially in the absence of clearly identifiable ovulatory states. Still more confounding
are conditions such as endometriosis, which lack a clear etiology, yet are linked to circulating hormone levels
[4].
In the present context, it is important to note that a high-fidelity, data-driven, robust and expansive
definition of normal ovulatory function does not currently exist. This makes defining ‘normal’ and ‘dysfunc-
tional’ a complex task, as dysfunction is usually defined as a deviation from normal. Because of this, we will
adopt a narrow definition of normal and consequently limit our ability to discover a different-from-normal
phenotype. Ideally, we seek an alternative to patterns in hormone dynamics to distinguish between ovu-
latory phenotypes, with the hope that identifying underlying mechanisms of dysfunction lies in our ability
to connect clinical symptoms with mechanisms that may not be apparent in hormone measurements alone.
Given the problems identified above, modeling and analysis at this level of detail is not possible.
In this paper we do not attempt to overcome all problems between the development of a model and the
use of the model to help improve human health at once, but rather focus on two. First, we begin with a
model and reduce it, which has two consequences: (1) reduction of identifiable pathologies by decreasing
the number of states and unknown parameters; and, (2) induction of a physiologic hypothesis about what
variables are important for representing the female endocrine system related to PCOS and endometriosis.
The result is a new endocrine model of ovulation. Second, we evaluate the model’s ability to represent
data, delineate the time-dependent differences between normal and abnormal cycles given a cycle length,
and we examine emergent phenotypes through analysis of the parameter space. Although model evaluation
is limited by data availability, we construct the evaluation methodology such that, given more data, a more
powerful, direct evaluation will be immediately possible.
1.1. Paper road map
In Section 2, we review the Graham-Selgrade model of ovulatory dynamics [5], which is the modeling
starting point. We then reduce this model by removing testosterone to create a new model of ovulatory
dynamics; this is our first result. In Section 3, we introduce the computational, evaluation, and data-related
machinery we use to validate the model and examine its ability to resolve and differentiate our narrowly
defined phenotypes. In Section 4, we follow with the computational validation of the new model as well as
our investigation of the model parameters to study clinical phenotypes.
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2. Ovulation Model and its Reduction
We develop a new endocrine model to describe essential processes in ovulation. This new model is
a reduction of a model developed by Graham and Selgrade that uses ordinary differential equations to
describe the ovulatory cycle under the influence of elevated androgens, namely testosterone [5]. Testosterone
is a major element in the Graham-Selgrade model because androgen excess, or hyperandrogenism, and
insulin resistance are frequently associated with ovulatory dysfunction related to PCOS. Although PCOS
is an important disorder with many open questions regarding its etiology [6], we presently aim to examine
generalized ovulatory dysfunction, which may or may not stem from previously defined clinical phenotypes,
e.g., PCOS. Moreover, while we reduce the model by eliminating testosterone as a state variable, testosterone
remains an implicit variable in the model; we verify testosterone-mediated dysfunction in the course of
validating the reduced model. To achieve this goal we work to reduce the model to limit the size of
parameter and state spaces, thereby reducing the complexity of the analysis and the data required to resolve
phenotypes. We choose to begin with the Graham-Selgrade model because we deem it more amenable to
reductions in the parameter space while retaining normal ovulatory dynamics, in contrast to other related
models that are based on delay differential equations [7, 8, 9].
2.1. The Graham-Selgrade model
The Graham-Selgrade model [5] is divided into three major subsystems: pituitary regulation, follicle
dynamics, and ovarian steroidogenesis. Collectively, the model consists of 12 state variables, tracking serum
concentrations of five important reproductive hormones (follicle stimulating hormone (FSH), luteinizing
hormone (LH), estradiol (E2), progesterone (P4), and testosterone (T)), along with precursors/intermediaries
of LH, FSH, and T. It also describes the dynamics of three follicular stages and of the follicle response to LH,
termed LH sensitivity. The final model contains 411 unknown parameters which are estimated by fitting the
model to data from the literature [1, 10]. The complete list of equations for the original Graham-Selgrade
model may be found in Appendix A.
2.1.1. Compartmental model description
The Graham-Selgrade model uses a compartmental framework to examine changes in ovulation due to
increased androgens. The model follows the approaches of [7, 8, 9] and comprises three major subsystems,
which describe changes in the pituitary-ovarian axis with mechanisms of steroidogenesis.
I. Pituitary regulation. LH and FSH are the primary hormones produced by the pituitary gland. Syn-
thesis and release of these hormones are regulated by ovarian steroid hormones, including E2, P4,
and T. The equations governing changes in FSH and LH are split between releasable (denoted FSHρ
and LHρ) and serum (denoted FSH and LH) pools of the hormones and incorporate stimulatory
and inhibitory feedback by ovarian steroids. Using this compartmental approach, we can differentiate
feedback processes governing pituitary hormone synthesis versus release.
Here we provide a generalized description of pituitary dynamics. Let H(t) denote the serum concen-
tration of a pituitary hormone (either FSH or LH) and Hρ(t) its releasable amount at time t. For
H = FSH, LH, the differential equations governing releasable and serum quantities have the form
dHρ
dt
= ksynthesis(·)− krelease(E2, P4)Hρ, (1)
dH
dt
= krelease(E2, P4)Hρ/V − δHH. (2)
Each k(·) term denotes a function of state variables and describes the change in hormone levels due
to the process indicated. Synthesis of FSH and LH is determined by different processes—with precise
1The model presented in [5] contains a typographical error in one of the equations, which omits one parameter (cΦ,T ) from
the total parameter count cited.
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arguments to ksynthesis omitted to reflect this—whereas their release is mediated solely by E2 and P4.
Release into the serum is scaled by the blood volume, V , and clearance of the hormones is assumed
to be a first-order process, with rate constant δH . Regardless of the highly nonlinear form of ovarian
feedback, the subsystem remains linear in Hρ and H. Collectively, the pituitary subsystem comprises
four differential equations, with Equations (1) and (2) defined explicitly for both FSH and LH.
II. Follicle dynamics. Follicle growth, maturation, and differentiation are assumed to occur in a series of
three sequential stages: (1) follicular, (2) ovulatory, and (3) luteal. We denote these using variables
Φ(t), Ω(t), and Λ(t), respectively. The follicular phase is characterized by recruitment and growth of
stimulated follicles. The ovulatory phase is characterized by ovum release from a designated follicle in
response to a mid-cycle surge in LH. Finally, the luteal phase is characterized by the formation and,
in the absence of fertilization, regression of the corpus luteum. The three follicular stages are modeled
as follows:
dΦ
dt
= krecruitment(T ) + kgrowth(FSH, T )Φ− kovulation(FSH,LH)Φ, (3)
dΩ
dt
= kovulation(FSH,LH)Φ− kluteal(S)Ω, (4)
dΛ
dt
= kluteal(S)Ω− kregression(S)Λ. (5)
Transitions to subsequent stages are unidirectional and depend on pituitary hormone levels. The
model also incorporates a role for T in follicle recruitment and growth. Graham and Selgrade further
define a new LH support variable, S(t), to model the tonic LH-dependence of growth and premature
regression of the corpus luteum. Specifically, S decays exponentially (with rate δS) to 0 in the absence
of LH and approaches a maximal level of 1 for sufficiently large LH:
dS
dt
= kactivation(LH)(1− S)− δSS. (6)
III. Ovarian steroidogenesis. Throughout the ovulatory cycle, follicles may produce E2, P4, and T. In-
tracellular steroid production is primarily FSH- and LH-dependent during a typical cycle and is
subject to functional maturation of individual follicles. This subsystem exploits the two-cell two-
gonadotropin theory of ovarian steroid production, which describes the differential functionality of
theca cells and granulosa cells within ovarian follicles [3]. The Graham-Selgrade model also introduces
a semi-mechanistic description of testosterone production for examining a role for insulin in promoting
hyperandrogenism. For Tγ(t) denoting the ‘intermediate’ concentration of T destined to be converted
into E2, we write
dTγ
dt
= kentry(LH,α)− karomatization(FSH)Tγ . (7)
In a growing follicle, theca cells compose the outermost layers of cells surrounding the ovum and
granulosa cells the innermost layers. Importantly, theca cells possess androgen (i.e. T) production
machinery and are stimulated by LH alone, whereas only neighboring granulosa cells can convert these
androgens into estrogens, in an FSH-dependent process called aromatization. Therefore, we consider
Tγ to reflect the average concentration of T that enters granulosa cells from theca cells.
Finally, we model the major ovarian outputs of the model: serum concentrations of E2, T, and P4:
dE2
dt
= kbasal,E − δEE2 + karomatization(FSH)Tγ · fE(Φ,Ω,Λ), (8)
dT
dt
= kbasal,T − δTT +
[
kovarian
production
(LH,α) + kperipheral
production
(LH,α)
]
· fT (Φ,Ω,Λ), (9)
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dP4
dt
= kbasal,P − δPP4 + ksecretion(LH) · fP (Φ,Ω,Λ). (10)
The first two terms in Equations (8)–(10) represent basal secretion by the adrenal gland and first-
order clearance of individual steroids, defined by rate constants kbasal,I and δI , respectively, where
I = E, T, P . The last term in each equation defines secretion of steroid hormones into the circulation,
which is assumed to occur immediately upon production. The average production rate per follicle
is multiplied by a function fI(Φ,Ω,Λ), I = E, T, P , that describes the relative contribution of each
follicular stage to the production of a given steroid.
Importantly, steroidogenesis is altered through feedback from FSH and LH, according to the two
cell-two gonadotropin theory. Whereas LH is required almost exclusively for T (theca only) and
P4 (theca and granulosa) production, FSH is entirely responsible for E2 (granulosa only). Because
P4 is an androgen precursor in the theca, it is assumed that circulating P4 is produced primarily
by granulosa cells for modeling purposes. To address insulin’s influence in ovulatory dysfunction,
the Graham-Selgrade model contains a detailed formulation of T production, wherein ovarian and
peripheral conversion of T from its precursors are treated as two distinct processes. In Equations (7)
and (9), the parameter α represents the relative degree to which insulin may increase T production.
2.2. A new model of endocrine regulation: Graham-Selgrade model reduction
A natural course of action in determining salient model behavior is global sensitivity analysis (GSA)
of parameters. This allows us to determine the relative sensitivity of model output to changes in the
parameters. There are multiple challenges associated with the Graham-Selgrade model that make GSA a
suboptimal next step in model analysis. First, the model contains considerably more parameters than the
data available for fitting. Second, coupling between state variables is highly nonlinear. Third, stable limit
cycles are not guaranteed for all parameter combinations. Collectively, standard GSA approaches provide
limited insight. In particular, a PRCC-based approached would be inappropriate, as simulations do not yield
monotonic hormone responses that can be interpreted in any meaningful way (preliminary work, not shown).
Alternatives such as the extended Fourier amplitude sensitivity test (eFAST) may also prove more useful,
as discussed in [11]. However, selection of appropriate model output remains a challenge. In light of these
observations, we hypothesize that structural reduction of the model may provide greater insight to relevant
and essential processes governing the typical ovulatory cycle. We may also use the resulting framework to
examine more general questions of ovulatory function separate from the pathologies associated with PCOS.
Here we introduce the major modifications to effectively reduce the number of unknown model parameters.
2.2.1. Removal of testosterone
Complete data sets that track the pituitary hormones, LH and FSH, as well as ovarian steroids E2 and
P4 during the course of an entire cycle are uncommon but not completely absent. What is missing is a
complete hormone profile that also includes androgen levels through the course of a normal ovulatory cycle.
Based on this information, we eliminate T (and hence insulin) entirely from the Graham-Selgrade model.
With this adjustment, we remove Equation (9) entirely and set α = 0 and T (t) = T0 for all t. We then
adjust the remaining differential equations as needed to eliminate T (and Tγ) coupling.
Effect on steroidogenesis. We assume that intermediate T transferred from theca to granulosa cells is im-
mediately converted into E2. Then using a similar reduction approach in [5] applied to a more mechanistic
steroidogenesis model, we set T˙γ = 0 and solve for Tγ . Substituting the resulting expression and the
original parameters into Equation (8) gives E˙2 = e0 − δEE2 + tg1F1(LH) · (Φ + ηΛS), where F1(LH) =
LH2/[κ1LH
2 + κ2LH + κ3]. We further observe that for sufficiently large LH, κ3  κ1LH2 + κ2LH, so
we redefine F1(LH) = LH/(LH + κ2) and rescale parameters accordingly (see Equation 19).
Notably, the reduced version of E˙2 removes the FSH-dependence on E2 production from the original
framework. For a normally ovulating cycle, we may then consider FSH to be permissive for E2 synthesis
within granulosa cells. Further, the time scale on which FSH alters follicular expression of aromatase—via
the steroidogenic acute regulatory protein— is significantly shorter (∼ minutes) than that of a typical cycle
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[12]. As such, we assume any tonic level of FSH allows for proper steroid synthesis, and the degree to
which this occurs depends solely on the functional maturation of follicles in the reduced model. Therefore,
we relegate FSH-dependent E2 production to a nonessential process and focus instead on other sources of
pathological behavior within the cycle.
Effect on pituitary regulation. In the original model, the influence of T is restricted to synthesis of releasable
LH: T is assumed to increase basal LH production and to prevent P4-mediated inhibition of all LH produc-
tion. To eliminate T from the necessary terms, we redefine the affected parameters given our assumption of
relatively constant T levels. In particular, we set vnew0L = v
old
0L T0/(KL,T +T0) and K
new
iL,P = K
old
iL,P (1+cL,TT0)
(see Equation 13).
Effect on follicle dynamics. In the original model, T serves two functions: (1) it influences the rate at
which very immature follicles enter stage Φ to begin gonadotropin-dependent growth and differentiation,
and (2) it increases follicle sensitivity to FSH signaling. To eliminate T from this subsystem, we note
that the originally estimated basal rate of T-mediated follicle recruitment is f0 ∼ O(10−3). It is therefore
unlikely that this process contributes substantially to the function of a normal cycle, and so we simply set
f0 = 0. Following our approach in the pituitary subsystem, we redefine the FSH sensitivity parameter to be
hnew1 = h
old
1 /(1 + cΦ,T ), provided that follicular FSH sensitivity remains constant throughout the menstrual
cycle (Equation 15).
2.2.2. Simplifying assumptions
In addition to eliminating T as a state variable, we make two simplifying assumptions to further reduce
the number of unknown parameters. These parameters are chosen in consideration of the important biological
components that must be maintained in order to consider the resulting model an accurate and useful
representation of the menstrual cycle under physiological conditions. Rather than focusing on a topologically
equivalent system, we focus on preserving plausible biological mechanisms.
FSH-dependent LH sensitivity. An essential event in ovulation is the upregulation of LH receptors in the
late follicular stage (stage Φ). This is an FSH-dependent process occurring within sufficiently mature
follicles. The Graham-Selgrade model assumes FSH increases follicle sensitivity to LH during stage Φ. In
the model reduction, we assume the maximal sensitivity parameter, h2 remains constant. This is a reasonable
simplification, as h2 ∼ O(103) and cΦ,F ·max
t
{FSH(t)} ∼ O(1) in the original model.
LH-dependent P4 production. P4 conversion within theca and granulosa cells requires enzymes that are
regulated by LH. The estimate for the half-maximal LH concentration, hp, that stimulates P4 production in
the original model is lower than the simulated LH concentration during the luteal phase (where P4 attains
peak concentration). Therefore, we assume that the steroid production per follicle is constant at the maximal
rate p in LH.
2.3. Reduced mathematical model equations
The new model is given by Equations 11–20 and contains 10 differential equations. With 27 unknown
parameters, we have reduced the parameter space by more than a third. Terms in the model that have
been altered due to removal of testosterone are boxed with a single line. Those that result from additional
simplifying assumptions as described in Section 2.2.2 are boxed with a double line. For comparison, the
original model equations are listed in Appendix A.
Releasable FSH:
dFSHρ
dt
=
vF
1 + cF,I
SΛ
KF,I+SΛ
− kF 1 + cF,PP4
1 + cF,EE22
FSHρ (11)
Serum FSH:
dFSH
dt
=
1
V
· kF 1 + cF,PP4
1 + cF,EE22
FSHρ − δFFSH (12)
Releasable LH:
dLHρ
dt
=
[
v0L +
v1LE
n
2
KnmL + E
n
2
]
· 1
1 + P4/KiL,P
− kL 1 + cL,PP4
1 + cL,EE2
LHρ (13)
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Serum LH:
dLH
dt
=
1
V
· kL 1 + cL,PP4
1 + cL,EE2
LHρ − δLLH (14)
Follicular phase:
dΦ
dt
=
 f1FSH2
h21 + FSH
2
− f2LH
2
h22 + LH
2
 · Φ (15)
Ovulatory phase:
dΩ
dt
=
f2LH
2
h22 + LH
2
· Φ− wSΩ (16)
Luteal phase:
dΛ
dt
=wSΩ− l(1− S)Λ (17)
LH support:
dS
dt
= sˆ
LH4
LH4 + h4s
(1− S)− δSS (18)
Serum E2:
dE2
dt
= e0 − δEE2 + tg1 LH
LH + κ2
· (Φ + ηΛS)
(19)
Serum P4:
dP4
dt
= − δPP4 + p ΛS (20)
3. Computational Methods and Model Evaluation
3.1. Terminology: physiological vs. mathematical cycles
To discuss model evaluation and results, we explicitly distinguish between physiological and mathemat-
ical notions of a ‘cycle’. When discussing properties of mathematical ovulation, we explicitly refer to the
inter-ovulatory interval (IOI), which denotes the length of time between consecutive simulated LH surges.
Physiologically, the IOI is equivalent to the time between two ovulatory cycles; however, multiple IOIs may
be required before the solution completes a single mathematical (limit) cycle. For clarity and consistency,
we restrict our generalized use of ‘cycle’ to refer to physiological ovulation and IOI to the calculated times
between these cycles.
3.2. Data
We use two data sets, one synthetic and one real. The first data set, the synthetic data set, is generated
using the original model [5]. This data set is used to show that the reduced model captures most of the
dynamics of the original model. The second data set is hormone data available in [1]. These data contain
average daily measurements for 33 normally cycling women during the course of one complete ovulatory
cycle for FSH, LH, E2, and P4. This second data set is used to demonstrate the both ability of the model
to estimate data well, and how to use the model to better understand physiology, given data.
3.2.1. Limitations and complexities of data and analytical challenges
The available data have three primary limitations that influence our work. First, recall that normal
is generally poorly defined, where ‘normal’ means no known pathophysiologic cycle features. Second, it is
known that there is substantial variation in IOIs even for an individual. For example, it is not uncommon
for the same person to have IOIs that vary from 20 to 40 days; these data obscure such intraindividual
variability by taking an average. And third, because the data are an average, they induce two potential
issues whose presence we may not be able to detect: (i) an average can fail to represent anyone if the mean
is not representative of the population, and (ii) an average smooths variability.
These data limitations impact the analysis in a fundamental way, most notably, the generalizability of
our results. We develop a phenotypic analysis subject to a standard IOI of 31 days and relative to average
hormone dynamics. It is surely possible that the average data do not represent individuals well. Moreover, it
is surely possible that hormone dynamics of different IOIs will be different. Finally, within the model, there
are two ways of generating variable IOIs: (1) one can change parameters that alter a constant IOI, or (2)
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one may define parameter regimes that allow for variable IOIs between consecutive ovulatory events. Given
that our data set is limited to a month and is an average, we cannot investigate the distinction between
these two model-based parameter differences. In short, the data set limits the generalizability of data-based
model validation, but our demonstration for how this pathway will work in the future remains relevant.
3.3. Model comparison: the reduced model vs. the original model
Equipped with computational machinery for estimating parameters given data, we want to demonstrate
the capability of identifying and defining phenotypes that emerge from the model. As previously mentioned,
we cannot move beyond what can be tested with data we have, but for our purposes this will not limit us.
We focus on two model-defined phenotypes, physiologic and pathophysiologic, and codify these as regular
or irregular cycle behavior, respectively. We assign these to cases of model-generated data by defining a
set of attributes that may distinguish between physiological and pathological ovulatory function. Given the
complex cross-talk in the reproductive endocrine system, analysis of hormone concentrations alone likely
provides insufficient insight into the subtleties of ovulatory dysfunction. To overcome this challenge, we
proceed by identifying a collection of parameters giving rise to predetermined regular or irregular cycle
behavior. To accomplish this, we implement an algorithm that allows us to carry out a comprehensive
evaluation of the reduced model.
3.3.1. An algorithm for comprehensive model evaluation
We introduce an algorithm to compare the new endocrine model to the original Graham-Selgrade frame-
work. In this section, we provide an overview (see Algorithm 1) and a detailed description of our implemen-
tation of the five-step algorithm.
Step 1: Synthetic data. We generate the synthetic data by numerically solving the system (A.1)–(A.12),
using the parameters in [5], for a sufficiently long time to approach a stable limit cycle for normal
ovulation. We then align the trajectories so that the LH surge occurs at the end of day 15 of the first
cycle. Finally, we extract daily data between days 0 and 30 and then, to avoid propagated numerical
inaccuracies, repeat the cycle twice more for each variable. We also expand the set of data to include
Φ, Ω, and Λ, under the assumption that follicular dynamics should follow a similar pattern to the
original model. With the exclusion of T from the model, we have a total of 7 state variables (including
FSH, LH, E2, and P4) with n = 93 data points each.
Step 2: Optimization. To determine how well the new model compares to the original model, we estimate
the 27 parameters of the reduced model by fitting output to the synthetic data. We capture essential
cycle behavior with the optimized parameters using a weighted least squares approach. For a given
variable Xi(t), where i ∈ {FSH,LH,E2, P4,Φ,Ω,Λ}, we first assign default weights wi = 1/Var(Xi(t))
to each data point at tj = 0, 1, . . . , 92. Because we cannot guarantee the expected behavior of follicular
Algorithm 1 Comprehensive model evaluation.
Step 1. Generate synthetic data set using Equations (A.1)–(A.12).
Step 2. Optimize reduced model parameters using weighted least squares and synthetic data.
Step 3. Run N Monte Carlo simulations, initialized with perturbed best-fit parameters from Step 2 and
refit to clinical data.
Step 4. Compute numerical solutions for each parameter profile generated in Step 3, and store resulting
hormone data over multiple cycles.
Step 5. Use results of Steps 3 and 4 to define salient phenotypes and distributions for each of the 27
reduced model parameters.
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dynamics, we do not incorporate additional time-dependent weights for i = Φ,Ω,Λ. However, for the
hormones we increase weights by variable factors at important peaks, troughs, and plateaus within the
data. These weights are adjusted to acquire the best qualitative fit to the data, with the understanding
that local minimization of the cost function may be sensitive to variation in weights and may not
produce a globally optimal solution.
Let yi represent the vector of measurements corresponding to reduced model output variable xi(ϕ),
defined by parameters ϕ. We define the optimization problem that minimizes the sum of the squared
error as
min
ϕ
1
|V | · n
∑
i
wi||yi − xi(ϕ)||2, (21)
where V = {FSH,LH,E2, P4,Φ,Ω,Λ} and denote the optimal parameter vector satisfying Equation
(21) by ϕ∗. We use Matlab’s fminsearch, which implements the Nelder-Mead simplex method, to
determine the optimal ϕ. In most cases, initial parameter guesses are taken from the original model.
In others, they are derived from the adjustments made in the reduction process, as described in Section
2.2. The best-fit parameters are listed in Table B.2 in the Appendix.
Step 3: Monte Carlo simulations. We determine the distributions of the 27 model parameters using
Monte Carlo simulations to generate a collection of best-fit parameters using various initial guesses in
the estimation scheme described in Step 2 and by comparing the output to data. We first assume that
the values in ϕ∗ represent mean quantities and that initial guesses, ϕ(0), are uniformly distributed
within ±10% of the mean. That is, ϕ(0)k ∼ U(0.9ϕ∗k, 1.1ϕ∗k) for k = 1, 2, . . . , 27. To ensure a represen-
tative sampling of N parameter combinations from each individual subinterval of length 1/N ranging
from 0.9ϕ∗k to 1.1ϕ
∗
k, we use Latin hypercube sampling (LHS) and randomly generate initial parame-
ter guesses for the Monte Carlo simulations (see [13] for further discussion on LHS). For each initial
parameterization we minimize a cost function similar to Equation (21), this time with measurements
yi, i ∈ {FSH,LH,E2, P4} taken from clinical data available in [1].
Step 4: Range of simulated model output. We numerically solve the reduced model over 93 days using
the estimated parameters and generate an ensemble of these solutions via Monte Carlo sampling. We
align each LH surge (assuming one exists) to day 15 and determine the length of each IOI. The LH
surge is defined to be a peak LH concentration that is followed by an apparent luteal phase; any other
local maxima in LH failing to meet this criterion are ignored. Because we have restricted our sampling
scheme in Step 3, we guarantee that the model does not approach a stable equilibrium. Although this
limitation does not capture complete ovarian failure (i.e., the absence of a cycle at all), it does allow
for reasonable comparisons in the presence of oscillatory dynamics.
Step 5: Phenotypes and parameter distributions.
(a) Defining phenotypes. We implement a two-step process for determining distinct phenotypes
using model output. First, we use the values of extreme IOIs to ensure that the presence of
abnormally long or short IOIs at any time is considered pathological. In particular, we assign a
regular phenotype to simulations resulting in both minimal and maximal IOIs between 25 and
35 days, which is the textbook standard range for normal ovulatory cycles [3]. We assign an
irregular phenotype to simulations failing to satisfy this criterion. Second, we compute the mean
squared error (MSE) between the data (LH, FSH, E2, and P4) and each simulation. Then we
use the minimal MSE attained by an irregular phenotype to define a threshold for secondary
regular phenotypes: regular + lo MSE refers to regular phenotypes with MSE strictly less than
the computed threshold, and regular + hi MSE to regular phenotypes with MSE at or above the
computed threshold.
(b) Computing parameter distributions. We construct empirical parameter distributions based
on the optimized parameter sets obtained from the Monte Carlo simulations. First, we apply the
primary (regular vs. irregular) phenotype classification criteria to the N Monte Carlo samples.
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Then we normalize the population sizes of individual phenotypes by subsampling the associated
parameter distributions at their respective frequencies to an arbitrarily chosen size of 2000.
3.3.2. Statistical Methods
The addition of a phenotype classification generates several interesting questions that may be explored
with the use of statistical and probabilistic tools.
Two-sample Kolmogorov-Smirnov (KS) test. In the present work, we seek phenotypic differences determined
by model parameters. The KS test is used to determine whether two samples are drawn from the same
distribution [14, 15]. The test uses the Kolmogorov-Smirnov statistic, which is defined as the L∞ norm of
the distance between two cumulative probability distribution functions. For each parameter, we then apply
ks.test, the R implementation of the two-sampled KS test, to analyze the phenotype-specific empirical
distributions generated from our simulations.
t-Distributed stochastic neighbor embedding (t-SNE). Beyond the structure manually imposed on the Monte
Carlo dataset, we are interested in determining whether distinct phenotypes can be identified in another
way. Patterns in the generated data may depend on any of 93 data points for each of four hormones, or any
of the 27 parameter estimates. Without a comprehensive understanding of the interplay between each of
these elements, we seek a methodology that will answer the binary question of whether there are inherent
differences (seen or unseen) between regular and irregular phenotypes. t-SNE is a machine learning tool for
reduction of high-dimensional data to lower dimensions [16]. We use the Rtnse package in R to apply the
t-SNE and determine whether phenotypes can be clearly clustered by a profile of select model parameters.
4. Computational Results
4.1. Comprehensive reduced model evaluation
4.1.1. Generalized model behavior
Following Steps 1 and 2 of Algorithm 1, we simulate the reduced model and compare results to the
original model. We then use the parameterized model to simulate testosterone-mediated dysfunction, as
further verification that the reduction is a plausible replacement of the original system.
Qualitative features. In Figure 1 we numerically solve the reduced model using the best-fit parameters and
compare the result to output from the original Graham-Selgrade model. The qualitative dynamics are well
captured, with the primary quantitative discrepancy related to P4. This arises due to an overshoot of the
data in the luteal stage Λ during the mid-luteal stage (roughly 3–7 days after the simulated preovulatory LH
surge, not shown). Since P4 levels are known to peak clinically around this time, we consider this behavior
to be within a physiologically relevant and normal range for the hormone. Further, because we assume
that the ovarian stages are crude approximations to actual follicular dynamics, there may be substantial
variability in the trajectories that may nevertheless yield normal ovulatory function, as illustrated in [10].
Verification of testosterone-mediated dysfunction. A fundamental change in the reduced framework is the
omission of T. Although absent from the model, we may still examine how T might influence pathological
ovulation. This approach also serves as proof of concept when using the reduced model in lieu of the original
one. To re-incorporate T into the present framework, we modify relevant parameters. Following [5], we let
α denote the degree of insulin influence, where α = 0 reflects a normal state with basal insulin (and hence
T) levels. Assuming T remains constant over time, we define its concentration using a linear function in α,
denoted Tα:
Tα = T0 · [1 + (δT − 1) · (1 + α)]/δT , (22)
where T0 is the initial T concentration in the absence of hyperinsulinemia and δT is the first-order clearance
rate of T from the blood, as defined originally. The parameters to be altered by T in the reduced model
are v0L, KiL,P , and h1. We only consider the case of normal luteinization (see [5] for details) because we
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Figure 1. Fit of reduced model to Graham and Selgrade model [5] over 61 days. FSH and LH are displayed in standard
international units according to the 2nd international reference preparation, where 1 IU FSH = 45 µg and 1 IU LH = 15 µg
[17]. Conversion factors are based on the NIH preparation used in [1].
have omitted FSH-dependent upregulation of follicle LH receptors, which would impact parameter h2. To
incorporate the necessary modifications to the current model, we redefine the parameters v0L → v0Lξ1,
KiL,P → KiL,P ξ2, and h1 → h1ξ3 for α > 0, where
ξ1 =
(β1 + T0) · Tα
(β1 + Tα) · T0 , (23a)
ξ2 =
1 + β2Tα
1 + β2T0
, and (23b)
ξ3 =
1 + β3
1 + β3Tα/T0
. (23c)
The ξi in Equations (23) determine the scaling of the model parameters as insulin influence increases
and are plotted in Figure 2. The constants βi are defined according to the original model, with the caveat
that bifurcation values of α may be shifted based on the values of these parameters. The derivation of the
ξi are given in Appendix C. In Figure 3, we plot the long-term local maximum and minimum values of
LH for 0 6 α 6 3. A stable limit cycle is roughly evident for α < 0.2, with an apparent period doubling
bifurcation giving rise to alternating LH surge amplitudes. Minimal LH levels remain relatively constant
until another apparent bifurcation occurs at α ≈ 2.7, where the system approaches a stable equilibrium.
This suggests that the reduced framework responds to elevated T through modified and eventual loss of
ovulatory function. Although the dynamic mechanisms governing ultimate dysfunction may differ from the
original model, we are able to capture disruptive behavior. Whereas LH and P4 are primary determinants
of disruption in the original model, subject to sustained oscillations, the reduced model exhibits disruption
through loss of periodicity. Nevertheless, there is some consistency among parameters v0L, KiL,P , and h1
in regulating endocrine defects.
4.1.2. Phenotype extremes
From Steps 3 and 4 of Algorithm 1, we obtain an ensemble of model trajectories. Figure 4 shows
primary hormone trajectories over 186 days for two model solutions, one regular and one irregular, as
defined in Step 5(a) of the evaluation algorithm. For reference, the timing of the LH surge for the regular
phenotype is indicated with a vertical line. Stable limit cycle behavior is exhibited for the regular cycle with a
characteristic length of 30.9 days. The irregular phenotype, however, consists of nonuniform behavior of the
major hormones. Specifically, the irregular cycle has a length of 80.7 days, with 19.5 and 61.2 days passing
between consecutive LH surges. Although hormone levels are relatively normal through the course of the
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irregular cycle, there are marked differences in hormone patterns that could suggest ovulatory dysfunction.
4.1.3. Important parameters: Identification and distributions
Using the results from Step 5(b) of Algorithm 1, we can use the Kolmogorov-Smirnov test to assess
whether each parameter distribution differs from its counterpart in the opposing phenotype. Results for
subsampled parameter distributions are illustrated in Figure 5. Each box is shaded according to the minimal
level of significance that allows us to accept the alternative hypothesis, i.e. that regular and irregular
distributions are statistically different. Darker shaded squares correspond to higher levels of significance.
Of the 27 parameters remaining in the reduced model, we identify eight that have significantly different
distributions between regular and irregular phenotypes, with p < 0.01 (indicated by ∗). These parameters
are given in Table 1. Our remaining analysis focuses on these eight important parameters.
4.2. Refined phenotypic features
To determine whether a correlation exists between important parameters and the accuracy of their ac-
companying numerical solutions when fit to clinical data, we calculate the mean squared error between the
model output and the measured data. Although we fail to demonstrate a clear mechanistic relationship
between any of the eight relevant parameters (not shown) and their impact on hormone dynamics or phe-
notypes, we do observe a threshold MSE value—estimated from the MC output—above which all irregular
phenotype results lie and below which roughly 85% of regular results lie. We use this threshold to assign an
additional subcategory to simulations belonging to the regular phenotype; solutions are either ‘lo MSE’ or
‘hi MSE’ when yielding MSE values below or above the computed threshold, respectively. It is important
to recall that there does exist a subset of parameters for which the IOI varies by 50%, where both regular
and irregular IOIs are observed yet the limit cycle length is fixed. Because of this, lo MSE implies both low
intra-cycle hormone variability compared with data and also low IOI variability.
In Figure 6, we compute 95% confidence intervals of simulated hormone concentrations over four months
to examine how hormone profiles influence these refined phenotypes. As before, we align the simulated LH
surge of the first cycle at day 15. Low MSE simulations exhibit the least variation across all cycles (green
regions). Beyond the first LH surge, high MSE regular phenotypes (left panel, teal regions) have more
variation in the timing of characteristic ovulatory events (e.g. LH surge and luteal formation) than low
MSE, but considerably less variation than the irregular phenotypes (right panel, gray region). As a result,
predictability of ovulation is reduced when we refine phenotypes.
On the other hand, if we are less strict with our definition of ‘normal’, we find that it is more difficult
to discern reproductive phenotypes. In Figure 7, we plot the 95% confidence intervals for all LH and
P4 trajectories satisfying the criterion that at least one IOI is between 30 and 32 days long (teal). For
comparison, we also include the 95% CI for applicable irregular trajectories (gray). Limited to information
on a single IOI, there is considerable overlap between opposing phenotypes, which may obscure our ability
to discern irregularities in hormone regulation. These results are important because they highlight how
insufficient data can both mask ovulatory dysfunction and obscure phenotype definition, discovery, and
analysis.
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Figure 5. Two-sample Kolmogorov-Smirnov test. Shaded according p-value. ∗p < 0.01.
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Table 1. Eight parameters identified as most important based on the Kolmogorov-Smirnov test. Parameters are ranked in
order from most (1) to least (8) significant, according to the p-value obtained.
Rank Name Description
1 η luteal E2 production;
2 vF maximal FSH synthesis rate;
3 h1 follicle sensitivity to FSH;
4 sˆ LH support maximal growth rate;
Rank Name Description
5 KmL half-maximal E2 stimulation level;
6 δs LH support decay rate;
7 l maximal luteolysis rate;
8 f1 maximal follicle growth rate.
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Figure 7. 95% confidence intervals (teal) of LH and P4 trajectories satisfying the criterion of at least one inter-ovulatory
interval of 30–32 days. Light gray: 95% confidence interval for irregular phenotypes satisfying IOI criterion. Dark gray:
maximal irregular % CI that fits within total CI (43% shown).
In Figure 8, we examine the distribution of median IOIs for each phenotype. Median IOIs (mean ± s.d.)
for the regular phenotype with lo and hi MSE are 30.89 ± 0.09 and 31.93 ± 1.72, respectively, whereas the
median irregular length is 32.49±3.57 days. As with hormone levels, we observe little variation among IOIs
in the lo MSE category and a significantly wider spread for the other categories. In terms of mathematically
versus clinically cyclic behavior, we find that although most simulations result in oscillations, many do not
exhibit limit cycle behavior with a characteristic IOI.
4.3. Dimensional reduction of phenotypes
To distinguish between refined phenotypes based on parameter estimates, we implement a t-SNE of the
parameter profiles according to the assigned phenotypes. We again limit our analysis to the eight significant
parameters found in Section 4.1.3. As such, we aim to reduce an eight-dimensional system to two dimensions
and visualize relative distances between individual objects. In Figure 9, we find that the algorithm produces
two distinct clusters. Irregular cycles and regular cycles yielding a high MSE are considered to be closer
to each other than to completely regular cycles with low MSE. Importantly, the MSE was not used as a
dimension in our analysis using t-SNE. This suggests that even with relatively normal ovulatory function, we
can cluster individuals exhibiting some level of abnormality based on a small number of model parameters.
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Figure 9. t-Distributed Stochastic Neigh-
bor Embedding of model results. Di-
mensional reduction of identified phenotypes
based on the eight significant parameters
η, vF , h1, sˆ, KmL, δs, l, f1 gives a
two-dimensional embedding of model output.
Specifically, distinct clusters emerge according
to secondary phenotypes, which are separated
according to MSE levels.
5. Discussion
We introduce a new, reduced endocrine model that inherently demonstrates both regular and irregular
phenotypes classified by the timing of ovulation. The model produces distinct phenotypes as a result of
altered time-independent parameter regimes and in the absence of disease-specific factors, e.g. testosterone-
mediated dysfunction in PCOS. Through a comprehensive model evaluation algorithm, we identify a subset
of model parameters that provide insight into physiological mechanisms of dysfunction. Further, the reduced
framework provides a testable hypothesis of model prediction: consistently similar inter-ovulatory intervals
(IOIs) between individuals likely reflect similar reproductive hormone dynamics. But, such consistency is
a limiting factor in our ability to broadly predict ovulatory function and highlights the fact that a small
set of parameters can produce large variations in ovulatory profiles. These results also imply that there is
potentially a many-to-one relationship between endocrine states, e.g., physiologic parameters, and observ-
able endocrine dynamics and dysfunction, e.g., hormone dynamics. This fuzzy causation is not uncommon
in physiologic systems or in biomedicine broadly; but to develop better clinical treatment, it is critical to
minimize the number of potential causes of an observable problem while maximizing the understanding of
the physiologic mechanics driving endocrine dynamics. While we further clarify these issues below—we iden-
tify potentially testable mechanisms that drive different endocrine dynamics and phenotypes—substantial
problems remain.
Based on the most significant parameters identified by the present work, the model highlights mechanisms
associated with pituitary hormone synthesis (vF , KmL), follicle growth (h1, f1), luteal dynamics (sˆ, δs, l),
and ovarian E2 production (η). However, the redundancy in the biological processes associated with these
parameters allows us to more succinctly characterize sources of dysfunction based on two major processes:
altered follicular growth and feedback associated with E2 concentrations.
In vitro experiments suggest that granulosa cells may be more sensitive to FSH in PCOS, affecting both
follicle growth stimulation [3]. Follicular growth is stimulated by FSH, and the maximal FSH synthesis rate
parameter modulates pituitary stores of FSH. In the irregular phenotype, there is tendency toward increased
FSH synthesis. Since FSH is coupled to the ovarian subsystem only through the follicular stage, changes
in FSH synthesis will primarily affect follicle growth in the reduced model. The present model reflects such
dysfunction, as the irregular phenotype is associated with both increased follicle growth rate and follicle
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sensitivity to FSH.
Variations in E2 are implicated in multiple manifestations of ovulatory dysfunction. For example, de-
creased E2 is characteristic of menopausal women. Prolonged exposure to elevated E2 has been associated
with ovulatory disruption in previous mathematical models [8, 18], and elevated E2 formation has been
found in in vitro PCOS models [3]. In addition, Higher E2 responsiveness In the current work, parameters
associated with luteal stage dynamics are altered in the irregular phenotype. In particular, appearance and
disappearance rates of LH support are increased and decreased, respectively. This supports greater ovarian
mass during the luteal phase, which contributes to significantly elevated E2 during this period. Simulated
irregular cycles are also associated with higher E2 production rates from functional luteal cells and increased
pituitary sensitivity to E2, which can prematurely trigger the LH surge. Elevated subthreshold E2 prolongs
suppression of FSH and LH release into the serum, thereby inhibiting follicle growth. In extreme cases, this
results in two ovulation events close together, followed by an increased period of ovulatory suppression. This
is exhibited in Figure 4, with a two-month lapse between ovulation events in the representative irregular
phenotype.
In the absence of testosterone-mediated modifications, all phenotypes in the new endocrine model exhibit
successful ovulatory events, albeit with varying frequencies. Further, the hormone concentrations arising
from irregular cycles lie within their respective physiological ranges. Interestingly, the range of IOI for
irregular phenotypes are consistent with the ranges reported for individuals near menarche or approaching
menopause [3]. Although the ovulatory defects in the present framework do not reflect those specific to
disorders like polycystic ovary syndrome, our results suggest that subtle mechanistic differences contribute to
altered ovulatory function and that hormone measurements alone are insufficient in identifying abnormalities.
It also appears that our ability to identify defects via reproductive hormones depends on the sampling
frequency of data.
The reduced framework is amenable to modifications allowing us to explore T-mediated ovulatory dys-
function. Clinically, it remains unclear how disruptions propagate in the face of hyperandrogenism. We find
that when we alter pituitary-specific processes—particularly with respect to LH production—and follicle
growth processes with linearly increasing levels of T, cyclic behavior ceases. Further, the steady state ap-
proached for sufficiently large insulin influence includes a clinically low level of LH. In contrast, LH is often
found to be elevated in PCOS populations, but with high interindividual variability. These results suggest
that we may not associate the T-mediated disruptions within the reduced framework with specific PCOS
symptoms, but rather as part of a more generalized manifestation of ovulatory dysfunction due to abnormal
responses in the pituitary-ovarian axis.
The over-arching goal is to use models for predictive decision support and to deepen our understanding
of physiology. We wish to not only understand mechanisms of function but also the factors that differen-
tiate those mechanisms. Endometriosis and PCOS are two high-impact disorders governed by physiology,
both with incompletely understood etiologies. We wish to shed insight on these disorders to better inform
intervention and treatment decisions. The current model and evaluation process allows us to delineate
dysfunction based on physiology. As constructed, the model is flexible enough to allow us to highlight
important—generalizable or disorder-specific—mechanisms of dysfunction.
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Appendix A. Original Graham-Selgrade Model Equations [5]
Releasable FSH:
dFSHρ
dt
=
vF
1 + cF,I
SΛ
KF,I+SΛ
− kF 1 + cF,PP4
1 + cF,EE22
FSHρ (A.1)
Serum FSH:
dFSH
dt
=
1
V
· kF 1 + cF,PP4
1 + cF,EE22
FSHρ − δFFSH (A.2)
Releasable LH:
dLHρ
dt
=
[
v0LT
KL,T + T
+
v1LE
n
2
KnmL + E
n
2
]
· 1
1 + P4
KiL,P (1+cL,T T)
− kL 1 + cL,PP4
1 + cL,EE2
LHρ (A.3)
Serum LH:
dLH
dt
=
1
V
· kL 1 + cL,PP4
1 + cL,EE2
LHρ − δLLH (A.4)
Follicular phase:
dΦ
dt
= f0 · T
T0
+
 f1FSH2(
h1
1+cΦ,T T/T0
)2
+ FSH2
− f2LH
2(
h2
1+cΦ,FFSH
)2
+ LH2
 · Φ (A.5)
Ovulatory phase:
dΩ
dt
=
f2LH
2(
h2
1+cΦ,FFSH
)2
+ LH2
· Φ− wSΩ (A.6)
Luteal phase:
dΛ
dt
= wSΩ− l(1− S)Λ (A.7)
LH Support:
dS
dt
=
sˆLHm
hms + LHm
· (1− S)− δsS (A.8)
Serum T:
dT
dt
= t0 − δTT + [t1G1 (F1 + cT,F2F2) + t2G1G2F1] · (A.9)
·
[
Φ + τ1Ω + τ2SΛ + τ3
(
1− Φ + Ω + Λ
Ψ
)]
Intermediate T:
dTγ
dt
= tg1G1G2F1 − tg2FSH
h3 + FSH
Tγ (A.10)
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Serum E2:
dE2
dt
= e0 − δEE2 + tg2FSH
h3 + FSH
Tγ · [Φ + ηΛS] (A.11)
Serum P4:
dP4
dt
= −δPP4 + pLH
LH + hp
· ΛS (A.12)
Functional Forms.
• Insulin-stimulated conditions (α > 0)
G1 = G1(α)
G2 = G2(α)
D(α) = LH2 [G2 +A] + LH [G2B +A · (B + C)] +A ·B · C
F1(LH,α) = LH
2/D(α)
F2(LH,α) = LH/D(α)
• Basal conditions (α = 0)
G1 = G2 = 1
κ1 = 1 +A
κ2 = B +A(B + C)
κ3 = ABC
D = κ1LH2 + κ2LH + κ3
F1(LH) = LH
2/D
F2(LH) = LH/D
Appendix B. Reduced Model Parameters
Pituitary Parameters
Parameter Value
vF 3219.9
KiFI 149.76
kF 3.0212
cFP 65.229
cFE 0.0024047
cFI 3.0188
v0L 308.35
v1L 44700
KmL 226.37
KiLP 3.2279
kL 0.67146
cLP 0.015844
cLE 0.00068867
Ovarian Parameters
Parameter Value
f1 1.0958
f2 46.225
h1 146.31
h2 798.39
w 0.23497
l 0.64178
s 2.6338
δS 0.38256
η 0.81426
κ2 8.276
hs 11.691
tγ1 6.3594
e0 9.6377
p 0.22851
Table B.2. Optimal parameters generated from fitting the reduced model to original model output. Listed here are the
estimated parameters. Other fixed parameters appearing in the model remain unchanged from [5].
Appendix C. Derivation of Testosterone-Dependent Terms
To incorporate testosterone implicitly in the reduced model, we need to modify parameters v0L, KiL,P ,
and h1. We will use p˜ to denote parameters used in the original Graham-Selgrade model, which we will then
redefine to incorporate into the reduced framework.
Derivation of ξ1. In the original model, basal LH synthesis occurs at rate v˜0LT/(T + β1), where β1 =
KL,T = 420. We assume for the reduced model that
v0Lξ1 = v˜0L
Tα
Tα + β1
,
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where v˜0L is redefined so that ξ1 = 1 when Tα = T0. That is, we define v˜0L = v0L(T0 + β1)/T0. It follows
that
v0Lξ1 = v0L
T0 + β1
T0
Tα
Tα + β1
= v0L
(β1 + T0) · Tα
(β1 + Tα) · T0 .
Derivation of ξ2. In the original model, P4 inhibition of LH synthesis is scaled by the factor K˜iL,P (1+β2T ),
where β2 = cL,T = 0.00959. Similar to the derivation of ξ1, we assume
KiL,P ξ2 = K˜iL,P (1 + β2Tα),
so that
K˜iL,P =
KiL,P
1 + β2T0
and KiL,P ξ2 = KiL,P
1 + β2Tα
1 + β2T0
.
Derivation of ξ3. In the original model, follicle sensitivity to FSH has the form h1/[1 + β3T/T0], where
β3 = cΦ,T = 0.19878. We assume
h1ξ3 =
h˜1
1 + β3Tα/T0
,
so that
h˜1 = h1(1 + β3),
which implies
h1ξ3 = h1
1 + β3
1 + β3Tα/T0
.
Appendix D. Empirical Distributions by Phenotype
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Figure D.10. Empirical cumulative distribution functions for reduced model parameters, separated by regular (black) and
irregular (gray) phenotypes. Parameters are listed, beginning from the top row, in order of decreasing significance.
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